Study finds few avacopan-induced liver injury cases in US amid FDA push to revoke approval

Study finds low rate of liver injury from avacopan amid FDA approval review

A U.S. study published in Arthritis & Rheumatology found that only 0.8% of patients treated with avacopan for ANCA-associated vasculitis developed drug-induced liver injury, with liver enzyme elevations being uncommon. The findings come as the FDA considers revoking approval for the drug following earlier safety concerns.